NEW YORK — Angle said Monday that it has signed an agreement to access NuProbe USA's proprietary pan-cancer next generation sequencing panel.
Under the terms of the deal, Angle has acquired an option for the exclusive worldwide rights outside of China to use NuProbe's panel for the analysis of circulating tumor cells (CTCs) alone or in combination with ctDNA.
Financial and other terms were not disclosed.
According to Angle, the panel — which has been validated on an Illumina sequencing platform — enables the detection of more than 6,500 DNA mutations in clinically relevant genes, including those with matched targeted therapies or therapeutics under development.
The UK-based company said the panel is expected to help its efforts to develop a pan-cancer molecular sequencing assay that uses CTC analysis or dual CTC and ctDNA analysis from a single blood sample. In addition, the panel is expected to be immediately useful to Angle customers using its Parsortix cell isolation platform.
"Dual analysis of CTCs and ctDNA can provide additional and complementary information which will provide pharma services customers with unparalleled and repeatable insights into a range of cancers, and in the longer term provide clinicians with the potential for continual optimization of personalized cancer treatment plans," Angle CSO Karen Miller said in a statement.
Angle said that it has already completed a pilot study of the Parsortix system in conjunction with NuProbe's panel in blood samples from breast, lung, and ovarian cancer patients. In all of the cancer types, more mutations were identified exclusively in CTCs, as compared to ctDNA alone, the company said.
NuProbe USA is the Houston-based subsidiary of NuProbe Global, located in Shanghai.